Ascletis Pharma Inc.
1672
Rangering i aksjer
#10617
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Aksjekurs
$0.7330173
Markedsverdi
$769.42M
Endring (1 dag)
-2.05%
Endring (1 år)
-39.92%
Land
CN
Handel Ascletis Pharma Inc. (1672)
Kategori
Healthcare
Historikk for aksjesplitt for Ascletis Pharma Inc. (1672)
Aksjen Ascletis Pharma Inc. (symbol: 1672) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én 1672-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 1672-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én 1672-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 1672-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
